🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are thrilled to sponsor the 2023 #OBIOInvestmentSummit - Canada’s premier health science investment event, happening in Toronto on Feb. 8-10. The Summit and Early Technology Showcase connect global investors with growing new companies and technology innovators. OBIO

Venture Fellow and Summer Analyst positions are open! The Lumira Venture Innovation Program (VIP) is looking for a new cohort of exceptional students eager to get involved in life sciences venture capital to join our team. Learn more and apply now! bitly.ws/zXuQ

February 28th is Rare Disease Day. Lumira Ventures along with Angelini Ventures through the Angelini-Lumira Biosciences Fund are proud to support the discovery and development of innovative therapies providing greater health outcomes for rare diseases. bitly.ws/AVR5

Tomorrow, March 2nd, Associate, Suman Rao will be speaking on a panel of fellow life sciences investors at the SickKids Industry Partnerships & Commercialization education series, sharing the best practices for innovators to be investment ready. Sign up: bitly.ws/AYwM

Proud to be a program sponsor for MaRS Impact Health 2023, May 3rd - May 4th! Looking forward to an exciting two days filled with panels, pitches, and insightful conversations with leading voices in healthcare! Hopefully, we see you there! lnkd.in/gQmw_nz

Tomorrow, May 2nd, Senior Principal, Nikhil Thatte will be speaking on the MaRS-adMare Therapeutics Accelerator Panel, along with fellow industry leaders to discuss what it will take to move the life sciences sector forward in Ontario.

We are pleased to announce the Angelini-Lumira Biosciences Fund's lead investment in Cadence Neuroscience. The financing will allow the company to advance clinical trials beginning with drug-resistance #epilepsy developed in partnership with Mayo Clinic. bit.ly/3IFVhQb

Congratulations John Reilly on your appointment as CEO of Damona Pharma! This marks an exciting chapter for both you and the company. We look forward to working with you and your strategic vision for the company on this remarkable journey ahead!

SAVE THE DATE: Life Sciences BC 8th annual Invest in BC presented by Lumira Ventures is November 2nd, 2023! Applications to pitch are open from July 31 – August 25! Learn more and register now: bit.ly/3Q0vTci #LSBCinvest #lifesciences #investinBC

Deka Biosciences, Inc., Closes a USD $20M Series B2 Financing! Supporting Deka's pipeline advancement and drug product manufacturing as they continue clinical trials following FDA approval to proceed with their IND application to evaluate DK210 (EGFR). bit.ly/3tgzJFa

Breaking News: Portfolio Company, Histosonics Inc., Awarded FDA Clearance for Edison® Histotripsy System. Granting market authorization for the breakthrough designated platform, for the non-invasive destruction of liver tumors using the science of histotripsy. bit.ly/45sfrps

Congratulations to portfolio company, enGene (Nasdaq:ENGN) on the debut as a publicly traded genetic medicines company! Learn more: bit.ly/3MmBffC

We are excited to co-lead the $105M Series A for COUR Pharmaceuticals, accelerating a unique platform treating autoimmune disorders, along with Alpha Wave Ventures, Roche Venture Fund, Pfizer, Bristol Myers Squibb, Angelini Ventures, and JDRF T1D Fund. bit.ly/3vVNDh5

Lumira Ventures was among over 15 new and existing investors participating in the $200M oversubscribed private placement financing of our portfolio company enGene (Nasdaq: ENGN). The financing will help fund the company's operating plan into 2027. bit.ly/4bFPCXa

Congratulations to our portfolio company Fusion Pharmaceuticals on its acquisition by AstraZeneca for $2.4B. Accelerating Fusion’s industry-leading radiopharmaceutical R&D, pipeline, and manufacturing, to transform cancer patient outcomes globally. bit.ly/3vi1FcT

Dive into the world of #VentureCapital & company creation with Lumira Ventures & CCRM_ca’s Rob Quirk on this episode of #CCRMpodcast. From funding insights to exciting innovations in #CGTs, it’s a must-listen for founders, with Krista Lamb! Stream at ccrm.ca/podcast

Significant milestone day for the #WHIMsyndrome community as the U.S. FDA has approved X4 Pharmaceuticals XOLREMDI™ (mavorixafor capsules), the first drug indicated for patients with WHIM syndrome! Congratulations to the X4 team on this breakthrough achievement! bit.ly/3y4VIB

Congrats to Lumira portfolio company, Endotronix, on FDA pre-market approval of their Cordella™ PA Sensor System for heart failure treatment! A big step forward for patient outcomes and heart failure management. 🎉 bit.ly/3KXyUq5

We’re pleased to welcome SpectraWAVE to the Lumira Ventures portfolio, supporting the company’s $50M Series B financing along with Johnson & Johnson, Deerfield Management, SV Health Investors, S3 Ventures, and other investors. Read more: bit.ly/3XDhtSQ

We are happy to announce the promotion of Suman Rao, PhD, to Principal at Lumira Ventures! This well-earned advancement recognizes Suman's outstanding contributions to the firm and her dedication to driving innovation in the life sciences sector. bit.ly/4j8bYV3